Both TOE monotherapy and its combination with PD-1/PD-L1 inhibitor 2 significantly elevated the frequency of M1-type macrophages within tumor-infiltrating lymphocytes (Figures 2C, D). The gene discussed is PDCD1; the disease is neoplasm.